I agree as well. I just hope that we all understand that
I agree as well. I just hope that we all understand that Leronlimab is the answer.
However... 100's of other companies with seriously bad SAE's also feel THEY are the answer. The FDA is doing its job and can't approve everybody. Especially those who haven't finished all 3 phases.
We all know we have the answer... But sifting through all the crap takes time. I'm with you and wishes they knew that we are the one. Like I said... everybody thinks they are the one. Who gets it first... awful BP who is currently controlling our SP because why... They are BP... They donate the most because they can. It sucks AND THEY HAVE THE LERONLIMAB from 20 years ago... which is what made them BP today. It'll be us in a few years as WE have the magic bullet now. For Covid, for cancer, for HIV, for NASH, for GvHD, and more.
I NEVER want to discount life as that is number one... That is why we are all still here. While it is my opinion that BP is trying to control CYDY through stock manipulation, I find it disgusting. Life less valuable than money? WTF. How do they live with themselves?
Of course I could be wrong on everything... and this is only my opinion. GLTA!
2
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
The Enduring Spirit of the Long March Remember the original Long March? Two years, 25,000 li, and countless struggles. It was more than a military campaign—it was a flame of hope burning in the bleakest of times. Even today, folks in China still nod to its spirit as they navigate the nation's economic and social landscape. You might ask, "Why hold onto an event from 90...
Continue Reading
Big Moves in Military Planning Alright, folks, here's the skinny on something that's bound to shake up the military sector: Watchtower Labs has kicked the door open after its stealthy beginnings with a hefty $35 million in seed funding. Investors like Shield Capital, Conviction, and Founders Fund are throwing their weight behind this AI-powered venture that's poised to...
Continue Reading
Navigating Construction's Risky Waters La-di-da, another day, another dollar lost—or won—in the construction zone. But hey, here comes Trimble waving a shiny new AI-driven flag that promises to shut down those wrench-tossing surprises in construction projects. They're calling it the Document Crunch, a tool that lets contractors review everything from drawings to...
Continue Reading
The landscape of cystic fibrosis treatment is on the cusp of a seismic shift, promising new therapies poised to redefine patient care and market dynamics. As we stand at the intersection of innovation and opportunity, the impending transformation is fueled by groundbreaking therapies, increased healthcare spending, and a stronger push for personalized medicine. The Winds...
Continue Reading
Trilogy Metals Completes Ambler Metals Field Work Alright, folks, let's dive into a mining story that should catch the discerning eye. Trilogy Metals (NYSE: TMQ) proudly wrapped up its 2026 field season at the Upper Kobuk Mineral Projects (UKMP), located in northwestern Alaska. And if you're neck-deep in the mining sector, this isn't just a thing on the periphery; it's a...
Continue Reading
Fielding Opportunities in a Revved-Up Market You're knee-deep in grease and exhaust, keeping your motorsport enterprise alive against the big dogs without losing grip on the little guy's budget. What if I told you there's a service out there talking your language – combining marketing prowess with AI smarts for as low as $350 a month? That's ALIVE and Track Rabbit...
Continue Reading
Big Moves in Legal Tech and Fundraising In the world of investing, where technology is always a step ahead, Intelligent Legal Solutions (ILS) and Anduin are cooking up a storm with their latest partnership announcement. Targeting private markets fund managers and law firms, these two tech players aim to ease the layered chaos that comes with fundraising by integrating...
Continue Reading
Why Cognizant's Move Matters Imagine being at the top of your game, only to realize you need more heavy-hitters to keep your edge. That’s this deal in a nutshell. Cognizant (NASDAQ: CTSH) is diving deep into AI-led enterprise transformation by scooping up DyFlex Solutions, a name with plenty of clout in the SAP ecosystem. What's Behind the DyFlex Acquisition? Founded in...
Continue Reading
The Anticipation Around Vermilion's Upcoming Results There's a buzz in the air about Vermilion Energy Inc.'s upcoming Q3 2026 financial results. Slated to hit the wires November 4th, before the sun rises on Wall Street, folks in the trade have their eyes peeled to parse through any morsels of data. The question on everyone's mind? Whether they're making the right moves to...
Continue Reading
Innventure's Murky Waters Just when you think you've seen it all, stuff like this reminds you nothing's safe in the market. The law folks at Stranch, Jennings & Garvey, PLLC are sniffing around Innventure, Inc. (NASDAQ: INV) like bloodhounds to see if there's been some hoodwinking going on. We're talking questions about funny business with a data center deal between...
Continue Reading
Top 5 Most Recently Viewed Articles
The S&P 500 isn’t just a bunch of random stocks; it’s home to about 500 companies where the heavyweights like Apple, Nvidia, and Microsoft play a huge role. Back then, these tech titans held a jaw-dropping market cap of around $9.8 trillion—yeah, that's about 19.7% of the entire S&P 500! You could practically feel the desks humming with excitement as Nvidia...
Continue Reading
Class Action Lawsuit Overview Against Celsius Holdings, Inc. Celsius Holdings, Inc. (NASDAQ: CELH), known for its innovative energy drinks and liquid supplements, is currently facing a class action lawsuit. This legal action arises from significant allegations regarding misleading financial statements and substantial losses suffered by investors during a defined Class...
Continue Reading
Exploring Strategic Alternatives for Growth Cellectar Biosciences, Inc. (NASDAQ: CLRB) is embarking on a thoughtful exploration of various strategic alternatives aimed at enhancing its innovative drug development pipeline and maximizing stockholder value. While the specific alternatives remain under consideration, possibilities could include mergers, acquisitions, and...
Continue Reading
Wells Fargo Issues Buy Rating for The Trade Desk Wells Fargo has recently begun its coverage of The Trade Desk (NASDAQ: TTD) with a favorable Buy rating, aiming for a price target of $150. This comes in anticipation of the company’s upcoming quarterly earnings report. Analysts are upbeat about the prospects due to a multitude of factors that are expected to play a...
Continue Reading
Vulcan V-PRO FLIGHT: Official Ball of DUPR The world of pickleball is experiencing a transformative partnership as the Vulcan V-PRO FLIGHT has been recognized as the Official Ball of DUPR (Dynamic Universal Pickleball Rating). This landmark decision encompasses all DUPR events, ensuring that the Vulcan ball will be used across various leagues, tournaments, clubs, and...
Continue Reading